Lynparza receives positive EU CHMP opinion for 1st-line
maintenance treatment of BRCA-mutated advanced ovarian cancer
maintenance treatment of BRCA-mutated advanced ovarian cancer
AstraZeneca and MSD’s Lynparza is the only PARP inhibitor to demonstrate
an improvement in progression-free survival for patients in this setting
an improvement in progression-free survival for patients in this setting
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc.inside the US and Canada) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending Lynparza(olaparib) as a 1st-line maintenance treatment of BRCA-mutated advanced ovarian cancer.
The recommendation is for the use of Lynparza tablets as a maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.